Top 2 Health Care Stocks That May Plunge In August
Top 2 Health Care Stocks That May Plunge In August
As of Aug 26, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
截至2024年8月26日，醫療保健板塊的兩隻股票可能向那些以動量爲主要交易決策標準的投資者發出真正的警告信號。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.
RSI是一種動量指標，它將股票在股價上升的日子裏的強度與在股價下跌的日子裏的強度進行比較。與股票價格的走勢相比，它可以讓交易員更好地了解股票在短期內的表現。當RSI高於70時，資產通常被認爲是超買的，據Benzinga Pro稱。
Here's the latest list of major overbought players in this sector.
以下是行業中超買的主要股票列表。
Beigene Ltd (NASDAQ:BGNE)
百濟神州有限公司（納斯達克：BGNE）
- On Aug. 7, BeiGene posted better-than-expected second-quarter financial results. "This was a tremendous second quarter and an inflection point as BeiGene achieved positive non-GAAP operating income with rapidly increasing global revenues and continued financial discipline. Having now reached this milestone, we will further build on our differentiated, strategic capabilities as a leading, global oncology innovator," said John V. Oyler, Co-Founder, Chairman and CEO of BeiGene. The company's stock gained around 19% over the past month and has a 52-week high of $219.64.
- RSI Value: 72.54
- BGNE Price Action: Shares of Beigene fell 0.9% to close at $193.82 on Friday.
- 在8月7日，百濟神州發佈了超過預期的第二季度財務結果。百濟神州的聯合創始人、董事長兼首席執行官John V. Oyler表示：「這是一個重要的第二季度，也是一個拐點，百濟神州實現了正向非通用會計原則運營收入，並且全球收入持續增長，繼續保持財務紀律。現在我們已經達到了這個里程碑，我們將進一步發展我們作爲全球領先的腫瘤學創新者的差異化戰略能力。」公司股票在過去一個月內上漲了約19%，並且52周內的最高點是219.64美元。
- RSI值：72.54
- 百濟神州的股價表現：Beigene股票在週五下跌0.9%，收盤價爲193.82美元。
Halozyme Therapeutics, Inc. (NASDAQ:HALO)
奧洛茲美醫療公司（納斯達克：HALO）
- On Aug. 6, Halozyme Therapeutics reported better-than-expected second-quarter financial results. "Our strong financial results reflect another quarter of double-digit royalty revenue, EBITDA and earnings growth. We remain on track to deliver on our financial guidance for the full year that was recently raised following the issuance and validation of a new EU patent covering the ENHANZE rHuPH20 product. In the quarter, we also expanded ENHANZE into neurology treatment with Roche's EU and UK approval of Ocrevus SC, while also extending our reach into auto-immune diseases with argenx's FDA approval for VYVGART Hytrulo for the treatment of CIDP," said Dr. Helen Torley, president and chief executive officer of Halozyme. The company's stock gained around 12% over the past month and has a 52-week high of $62.86.
- RSI Value: 76.12
- HALO Price Action: Shares of Halozyme Therapeutics gained 1.8% to close at $62.72 on Friday.
- 8月6日，奧洛茲美醫療報道了超出預期的第二季度財務業績。"我們強勁的財務業績反映出雙位數的版稅收入、EBITDA和盈利增長的又一個季度。在最近針對ENHANZE rHuPH20產品的歐盟專利發行和驗證後，我們仍然堅定地執行全年財務指引。在這一季度，我們還通過Roche的歐盟和英國批准的Ocrevus SC將ENHANZE擴展到神經系統治療，同時通過argenx的Vyvgart Hytrulo獲得了CIDP治療的FDA批准，也擴大了我們在自身免疫疾病領域的影響力，"Halozyme總裁兼首席執行官Helen Torley博士說。該公司的股票在過去一個月上漲約12%，52周最高價爲62.86美元。
- RSI數值：76.12
- HALO價格走勢：奧洛茲美醫療的股票在上週五上漲了1.8%，收於62.72美元。
Read More:
閱讀更多：
- Jim Cramer Praises L3Harris Technologies, Says Intel Is 'Getting Whacked' By AMD: 'I Much Prefer...'
- 吉姆·克拉默讚揚l3harris technologies，稱英特爾正在受到AMD的打擊：'我更喜歡......'
譯文內容由第三人軟體翻譯。
